Latest filing published 08 Jun 2026 for Aclaris Therapeutics, Inc.. Read the official filing
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
William D. Humphries (board member) discloses dealings in 4 companies, chiefly Aclaris Therapeutics, Inc., STRATA Skin Sciences, Inc. and Clearside Biomedical, Inc. The record holds 12 filings, for trades running from 20 July 2021 to 5 June 2026.
Every open-market trade on record is a purchase: 2 purchases worth €48k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants and 8 option exercises.
The record was last updated on 8 June 2026 with an option exercise in Aclaris Therapeutics, Inc. The last insider purchase was made public on 28 March 2022, 1,665 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations